Alzheon

Alzheon, Inc. is a clinical-stage biopharmaceutical company based in Framingham, Massachusetts, developing oral small-molecule product candidates and diagnostic assays for Alzheimer's disease (AD) and other neurodegenerative disorders. Its work centers on inhibiting protein misfolding and aggregation, specifically blocking the formation of neurotoxic soluble beta-amyloid oligomers upstream in the amyloid cascade, in contrast to infused anti-amyloid antibodies that clear insoluble plaque.

The lead program, valiltramiprosate/ALZ-801, is an oral, twice-daily (265 mg tablet) valine-conjugated prodrug of tramiprosate developed for mild cognitive impairment due to AD in APOE4/4 homozygotes. The company states the valine conjugation improved pharmacokinetics and gastrointestinal tolerability relative to tramiprosate, with a brain-to-plasma ratio of roughly 40% and lower inter-patient variability (~25%), and that long-term safety has been evaluated in approximately 2,000 AD patients. ALZ-801 received FDA Fast Track designation in 2017 for Alzheimer's disease. The pivotal APOLLOE4 Phase 3 trial (NCT04770220) was a 78-week double-blind, randomized, placebo-controlled study in APOE4/4 early AD subjects; it screened over 6,000 patients and enrolled 325. A two-year, 84-patient Phase 2 biomarker trial (NCT04693520) in APOE4 carriers, including 31 APOE4/4 homozygotes, completed in the second half of 2023 and entered a fourth-year extension.

Beyond ALZ-801, the pipeline includes ALZ-507, an oral once-daily next-generation anti-amyloid aggregation inhibitor with a stated APOE4 corrector mechanism, positioned for Alzheimer's disease prevention as well as Alzheimer's disease, Down syndrome-associated dementia and cerebral amyloid angiopathy; the ALZ-700 series of once-daily oral prodrugs of ALZ-507 in discovery for dry age-related macular degeneration; and an undisclosed small-molecule anti-aggregation discovery library for neurodegenerative disorders.

Founding story

Alzheon was founded in 2013 by Martin Tolar, MD, PhD, and its development of valiltramiprosate is based on more than a decade of company research into the biology of Alzheimer's disease.

Business model

Alzheon develops proprietary small-molecule drug candidates and diagnostic assays in-house through clinical trials, funded by private and institutional equity financing and grant support, including a grant from the National Institute on Aging that helped support the APOLLOE4 Phase 3 trial. In 2024 management stated it had built commercial infrastructure over the prior two years and was confident in a go-it-alone strategy for a U.S. launch of ALZ-801 while building ex-U.S. channels and capabilities.

No approved products; valiltramiprosate is an investigational agent not approved anywhere in the world. Prospective revenue would come from commercialization of ALZ-801 following regulatory approval.

Traction

Completed a Phase 2 biomarker trial in 2023 with reported biomarker effects and clinical stabilization over two years, followed by a fourth-year extension; completed the pivotal APOLLOE4 Phase 3 trial with topline results announced in April 2025 reporting cognitive and functional improvement in a prespecified MCI-stage analysis; peer-reviewed publication of Phase 3 results in October 2025; and first subject dosed in the Phase 1 study of ALZ-507 in April 2026. FDA Fast Track designation was granted in 2017.

Latest developments

In 2025-2026 Alzheon reported peer-reviewed publication of the pivotal APOLLOE4 Phase 3 results (October 2025) and of evidence supporting hippocampal volume as a surrogate marker of clinical benefit (December 2025); presented plasma biomarker results showing early, consistent decreases in p-tau217 associated with cognition, function and brain atrophy measures (February 2026); presented clinical, imaging and fluid biomarker data at AD/PD 2026 and neurovascular protection and low-ARIA safety data at AAN 2026 and AAIC 2026; and dosed the first subject in the Phase 1 study of ALZ-507 (April 2026). Media coverage in July-August 2026 reported a 2.5-year cognitive benefit in the APOE4/4 MCI subgroup and reductions in plasma p-tau217 in early Alzheimer's disease.